Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended August 31, 2005 (First Quarter of Fiscal 2006)
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for food producers) and Animal Safety (veterinary instruments, consumables, and rodenticides).
Key Financial Metrics
| Metric | Q1 2006 (Aug 31, 2005) | Q1 2005 (Aug 31, 2004) |
|---|---|---|
| Net Sales | $16,778,000 | $15,212,000 |
| Gross Margin | $8,841,000 (53%) | $7,505,000 (49%) |
| Operating Income | $3,105,000 | $2,430,000 |
| Net Income | $2,140,000 | $1,584,000 |
| Diluted EPS | $0.25 | $0.19 |
| Cash & Marketable Securities | $3,552,000 | N/A |
| Working Capital | $25,074,000 | N/A |
| Long-Term Debt | $0 (No amounts drawn on $15M line of credit) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 10.3% year-over-year. The Animal Safety segment drove growth with a 13.5% increase, led by a 42.4% surge in rodenticide sales. Food Safety sales rose 6.7%, driven by Natural Toxins and Allergens.
- Margin Expansion: Gross margin improved from 49% to 53% due to favorable product mix and operational efficiencies from consolidated facilities in Lexington and Lansing.
- Profitability: Net income increased 35% to $2.14 million. Operating income rose 28% to $3.11 million.
- Cash Flow: Net cash provided by operating activities was $1.758 million, slightly down from $1.770 million in the prior year, primarily due to increased investment in accounts receivable and inventory.
- Balance Sheet: Accounts receivable increased by $1.479 million, and inventory increased by $908,000 compared to the prior fiscal year-end.
Outlook, Risks, and Unusual Items
- Guidance: Management explicitly states it does not provide forecasts of future performance. Historical results are not necessarily indicative of future results.
- Unusual Items: Other income increased by $171,000, largely due to $160,000 in grant revenue recognized from Ingham County related to employee hiring allowances.
- Acquisitions: The company acquired the distribution business of Biologische Analysensysteme GmbH (BAG) in Germany and the UriCon product line for companion animal health in late fiscal 2005.
- Risks: Key risks include competition, dependence on key employees, weather impacts on agriculture, integration of acquisitions, and foreign currency exposure (primarily British Pound), though the company does not currently hedge these exposures.
- Liquidity: Management believes existing cash and a $15 million revolving line of credit are sufficient for foreseeable needs, though future capital needs for product commercialization or acquisitions may require equity issuance or additional financing.
Investor Verification Checklist
- Verify the sustainability of the 42.4% growth in rodenticide sales, which was driven by specific customer needs for pest eradication.
- Monitor the increase in Days Sales Outstanding (DSO) from 56 to 58 days to ensure collection trends remain within normal ranges.
- Assess the impact of the new facilities in Lexington and Lansing on future margin expansion and production capacity.
- Review the status of the $1.25 million stock repurchase program (893,000 shares purchased to date).
- Confirm the timeline for adopting FASB Statement No. 123(R) regarding stock-based compensation, currently planned for the first quarter of fiscal 2007.